However, the sensitivity of blood samples for EGFR evaluation is globally low for solid tumors at an early stage of NSCLC, given the low number of free nucleic acids circulating in the blood and/or of the low number of CTC detections associated with an EGFR mutation [47,48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.